Forest Ray

Articles Authored by Forest Ray
Ampel will use the signature to develop FibroGene, a fibromyalgia blood test that the company expects to launch next year.
The company is developing a nonsurgical approach to help increase testing rates and lower the time to diagnosis for endometriosis.
Invitae Bets on Oncology Portfolio to Drive Growth as it Streamlines, Integrates Test Services
Premium
In the wake of last year's massive restructuring, Invitae is focused on developing its Personalized Cancer Monitoring product while integrating other oncology offerings.
Juno Diagnostics Lowers Barriers to Noninvasive Prenatal Testing With At-Home Sample Collection
Premium
The Hazel assay uses finger prick amounts of blood, from which it immediately separates plasma that can be shipped at room temperature for chromosomal analysis.

As Alzheimer's Dx Comparison Study Wraps Up, Researchers Plan to Add Genomic, Proteomic Profiling
Premium
Results from the Global Alzheimer's Platform cross-sectional study are expected in July 2023 with a second longitudinal study to be finished by the end of 2024.
Strong Signatera volumes fueled revenue growth and helped lift the firm's financial guidance despite questions raised by California regulatory action.
Myriad expects new product launches, strategic mergers, positive reimbursement decisions, and rising test volumes to drive growth despite current sagging revenues.
UCLA researchers developed an extracellular vesicle-based surface protein assay for early-stage hepatocellular carcinoma.
CareDx Q2 Revenues Grow 9 Percent but Miss Estimates as Firm Lowers Full-Year Guidance
Revenues rose 9 percent on test service growth, as the company’s net loss swelled to $21.7 million from $1.9 million in Q2 of last year.
Natera Q2 Revenues Rise 40 Percent on Higher Test Volume
Strong growth in Signatera volumes drove higher revenues, and along with gains in market share, Natera increases its guidance.